Buprenorphine

Buprenorphine is a semisynthetic opioid derived from thebaine, an alkaloid of the opium poppy. Pharmacologically it is best known as a partial agonist at the mu-opioid receptor, a property that gives it a distinctive safety and clinical profile ^[2]. It was first synthesized in the 1960s and entered human use in the 1970s, gaining approval as an analgesic and, in the early 2000s, as a treatment for opioid use disorder ^[3].

Its most prominent role today is in the treatment of opioid use disorder, where it is used both to ease withdrawal and as long-term maintenance therapy that reduces cravings and the risk of relapse; alongside methadone it is considered a mainstay of opioid agonist treatment ^[1][3]. Because it is a partial agonist, buprenorphine produces a ceiling effect on some opioid actions, including respiratory depression, which contributes to a wider margin of safety than full agonists such as methadone or heroin ^[1]. It is also used to manage moderate to severe pain, including in palliative care, where its profile can be advantageous in medically complex patients ^[2].

In the United States buprenorphine is a Schedule III controlled substance, reflecting a recognized but comparatively lower potential for misuse than Schedule II opioids, and access to it for addiction treatment has been progressively broadened. For opioid use disorder it is frequently formulated together with the opioid antagonist naloxone, a combination designed to discourage injection misuse because naloxone can precipitate withdrawal if the product is dissolved and injected ^[1].

Buprenorphine is available in a notably wide range of formulations, including sublingual and buccal films and tablets, transdermal patches, long-acting injections, and an implant. Many of the products used for addiction treatment pair buprenorphine with naloxone, while some pain and induction products contain buprenorphine alone ^[2][3].

The signature buprenorphine hazard is precipitated withdrawal: because it out-competes full agonists at the receptor, taking it while other opioids are still on board can throw you into fast, severe withdrawal, so induction waits until you are already in objective withdrawal (clinicians use the COWS scale). The ceiling effect makes overdose on buprenorphine alone unlikely in tolerant adults, but that protection evaporates when it is combined with other central nervous system depressants; mixing it with benzodiazepines, alcohol, or other sedatives can flatten the ceiling and cause fatal respiratory depression, and most buprenorphine-involved deaths trace back to exactly those combinations or to injection misuse.

It still produces ordinary opioid side effects (constipation, nausea, sweating, sedation, headache) and it creates physical dependence, so stopping abruptly brings withdrawal. Suboxone adds naloxone purely as an abuse deterrent; taken under the tongue as directed the naloxone barely absorbs, but if the film is crushed and injected the naloxone becomes active and triggers withdrawal. Other cautions include QT considerations at high doses, liver monitoring, and serious danger to opioid-naive people and children, since accidental pediatric exposure can be lethal. In the US it is a Schedule III controlled substance.

The interaction that kills people is with sedatives. Benzodiazepines, alcohol, gabapentinoids and other central nervous system depressants add to buprenorphine's respiratory depressant effect, and its ceiling on respiratory depression does not hold once a second depressant is present; most fatal buprenorphine cases involve a benzodiazepine.

Metabolism runs through CYP3A4 to norbuprenorphine. Strong inhibitors such as ketoconazole, clarithromycin and ritonavir raise buprenorphine exposure, while inducers such as rifampin, carbamazepine, phenytoin and efavirenz lower it enough to precipitate withdrawal.

Because buprenorphine is a high affinity partial agonist, it displaces full mu agonists from the receptor and blunts their effect; started too soon after a full agonist it precipitates withdrawal, and naltrexone or naloxone does the same. Serotonergic drugs raise serotonin syndrome risk, MAO inhibitors are contraindicated with opioids generally, and buprenorphine prolongs the QT interval modestly, which matters alongside other QT prolonging agents.

Checking a whole stack? Run it through interactions + stacks.